Results of PREVENT III: A multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery
Top Cited Papers
- 1 April 2006
- journal article
- research article
- Published by Elsevier BV in Journal of Vascular Surgery
- Vol. 43 (4), 742-751.e1
- https://doi.org/10.1016/j.jvs.2005.12.058
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Excess Dosing of Antiplatelet and Antithrombin Agents in the Treatment of Non–ST-Segment Elevation Acute Coronary SyndromesJama-Journal Of The American Medical Association, 2005
- Risk factors, medical therapies and perioperative events in limb salvage surgery: Observations from the PREVENT III multicenter trialJournal of Vascular Surgery, 2005
- Design and rationale of the PREVENT III clinical trial: edifoligide for the prevention of infrainguinal vein graft failure.Vascular and Endovascular Surgery, 2005
- Transcription Factor Decoys for the Prevention of Vein Bypass Graft FailureAmerican Journal of Cardiovascular Drugs, 2003
- Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapyThe Journal of Thoracic and Cardiovascular Surgery, 2001
- Cell Cycle ProgressionCirculation, 1998
- A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo.Proceedings of the National Academy of Sciences of the United States of America, 1995
- Stranger in a strange land: The pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteriesProgress in Cardiovascular Diseases, 1991
- Regulation of Gene Expression with Double-Stranded Phosphorothioate OligonucleotidesScience, 1990
- Present status of reversed vein bypass grafting: Five-year results of a modern seriesJournal of Vascular Surgery, 1990